<DOC>
	<DOCNO>NCT00034255</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single multiple dos intramuscular INGAP Peptide give first time humans potential treatment diabetes .</brief_summary>
	<brief_title>Single Dose 34-Day Tolerance Study INGAP Peptide Insulin Deficient Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Patients meet follow inclusion criterion screen consider admission study . Stage 1 Stage 2 : 1 . Male female patient , type 1 diabetes mellitus 18 70 year age , type 2 diabetes mellitus 30 70 year age . 2 . Patients insulin deficient diagnose type 1 type 2 diabetes mellitus , currently well manage insulin , without metformin . 3 . Patients stable dos insulin treatment 90 day prior study randomization . Patients meet follow exclusion criterion screen enrol study : 1 . Patients history clinically significant retinopathy , symptomatic autonomic neuropathy , unstable angina , kidney problem . 2 . Patients uncontrolled untreated significant pulmonary , neurological condition , cardiovascular disease , include hypertension , congestive heart failure , angina , peripheral vascular disease . 3 . Patients receive investigational product within 30 day admission study . 4 . Patients history clinical evidence multiple organ autoimmune disorder . 5 . Patients medical condition , serious intercurrent illness , extenuate circumstance would significantly decrease study compliance , include prescribe followup . 6 . Patients lactate breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2003</verification_date>
</DOC>